Martin H. Steinberg MD
Professor, Hematology & Medical Oncology
Professor, Pathology & Laboratory Medicine
75 E. Newton St | (617) 414-1020mhsteinb@bu.edu

Sections
Hematology & Medical Oncology
Centers
Center of Excellence in Sickle Cell Disease
Center for Regenerative Medicine
Evans Center for Interdisciplinary Biomedical Research
Biography
Martin H Steinberg, MD, is a hematologist/internist whose clinical and research focus has been on disorders of the red blood cell with special emphasis on sickle cell disease. He has published 450 articles and 3 textbooks on the science and clinical features of sickle cell disease and related disorders. A graduate of Cornell University and Tufts University School of Medicine he completed post-graduate training in New York and Boston. He conducts basic, translational and clinical studies devoted to understanding the pathophysiology and genetic basis of sickle cell phenotypic heterogeneity. He modeled the HbF concentration among red blood cells showing that only patients with very high HbF levels were likely to have major benefit, therefor setting a standard for HbF induction therapies. He identified cis- and trans-acting elements that help explain the high HbF levels of Saudi patients from the Eastern Province whose sickle hemoglobin gene is associated with the Arab-Indian haplotype. Using candidate gene, genome-wide association studies and next-generation sequencing to understand the genetic determinants of sickle cell disease heterogeneity, Dr. Steinberg and his coworkers modeled disease severity and selected subphenotypes of disease to discover hitherto unsuspected genetic associations. He has also reimagined the pathophysiologic features of sickle cell anemia, establishing with his collaborators a new widely accepted paradigm that the pathophysiology of sickle cell disease is a combination of both sickle vasoocclusion and intravascular hemolysis that has important prognostic and therapeutic implications. He also reported the first of a new class of hemoglobin disorders, the thalassemic hemoglobinopathies, wherein a single exonic mutation causes both a variant hemoglobin but also phenotype of thalassemia because of hemoglobin hyper-instability and catabolism.
Other Positions
Websites
Center of Excellence in Sickle Cell Disease
Hematology & Medical Oncology Faculty
Education
MD, Tufts University School of Medicine, 1962
AB, Cornell University, 1958
Publications
Ribeil JA, Pollock G, Frangoul H, Steinberg MH. An integrated therapeutic approach to sickle cell disease management beyond infancy. Am J Hematol. 2023 May 12. PMID: 37170801.
Published on 11/30/2022Sebastiani P, Steinberg MH. Fetal hemoglobin per erythrocyte (HbF/F-cell) after gene therapy for sickle cell anemia. Am J Hematol. 2023 Feb; 98(2):E32-E34. PMID: 36420999.
Published on 10/17/2022Cyrus C, Vatte C, Al-Nafie A, Chathoth S, Akhtar MS, Darwish M, Almohazey D, AlDubayan SH, Steinberg MH, Al-Ali A. miRNA Expression Associated with HbF in Saudi Sickle Cell Anemia. Medicina (Kaunas). 2022 Oct 17; 58(10). PMID: 36295630.
Published on 9/8/2022Minniti C, Brugnara C, Steinberg MH. HbSC disease: A time for progress. Am J Hematol. 2022 Nov; 97(11):1390-1393. PMID: 36073655.
Published on 7/1/2022Steinberg MH. World Sickle Cell Day 2022: Progress & prospects. Indian J Med Res. 2022 Jul; 156(1):10-13. PMID: 35946231.
Published on 4/26/2022Steinberg MH. Targeting fetal hemoglobin expression to treat ß hemoglobinopathies. Expert Opin Ther Targets. 2022 Apr; 26(4):347-359. PMID: 35418266.
Published on 3/19/2022Steinberg MH. Fetal hemoglobin in ß hemoglobinopathies: Is enough too much? Am J Hematol. 2022 Jun 01; 97(6):676-678. PMID: 35253929.
Published on 3/15/2022Heitzer AM, Longoria J, Rampersaud E, Rashkin SR, Estepp JH, Okhomina VI, Wang WC, Raches D, Potter B, Steinberg MH, King AA, Kang G, Hankins JS. Fetal hemoglobin modulates neurocognitive performance in sickle cell anemia?,??. Curr Res Transl Med. 2022 Jul; 70(3):103335. PMID: 35303690.
Published on 2/17/2022Steinberg MH. Fetal-like Hemoglobin in Sickle Cell Anemia. N Engl J Med. 2022 02 17; 386(7):689-691. PMID: 35172060.
Published on 2/16/2022Klings ES, Steinberg MH. Acute chest syndrome of sickle cell disease: genetics, risk factors, prognosis, and management. Expert Rev Hematol. 2022 Feb; 15(2):117-125. PMID: 35143368.
Media Mentions
Published on 4/3/2023
First CRISPR therapy seeks landmark approval
Published on 3/11/2022
Gene Therapy Trials for Sickle Cell Disease Hold Hope for Durable Effects
Published on 2/18/2022
Sickle cell disease could have a cure soon, gene therapy shows good results in clinical trial
Published on 10/6/2020
Fulcrum’s FTX-6058 Shows Promising Efficacy as SCD Therapy in Disease Models
View full list of 4 media mentions.